Critical Care
CytoSorbents
Leader in Critical Care Immunotherapy
Leading the Prevention or Treatment of Life-Threatening Inflammation in the ICU and Cardiac Surgery using CytoSorb® Blood Purification
CytoSorb®, is E.U. approved, with 46,000+ treatments; distributed in 53 countries
Organ failure occurs when vital organs stop working, causing nearly half of all deaths in the ICU.
CytoSorb® targets the $20+ billion opportunity in critical care and cardiac surgery
Approved in the European Union as the first specifically approved extracorporeal cytokine adsorber
Benefits Of CytoSorbents
- Broad indication for use where cytokines are elevated
- Removes cytokines and many other inflammatory mediators such as free hemoglobin, bacterial toxins, myoglobin, and activated complement
- Safe and well-tolerated: 46,000+ cumulative treatments delivered, up from 27,000 a year ago
- Proprietary patented technology with multiple patents pending worldwide
- Manufactured at our ISO 13485 certified facility in New Jersey